Cross-Disciplinary Frameworks for GLP-1 Prescribing in Patients With Co-Occurring Eating Disorders

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Journal of Eating Disorders. https://doi.org/10.1186/s40337-026-01696-6  
Dr. Gemma Sharp  et al.

Points

Adelaide University researchers evaluated the therapeutic overlap between obesity and eating disorders driven by increasing clinical utilization of GLP-1 receptor agonists.
Epidemiological data indicate that approximately one in three Australian adults lives with obesity, while five percent experience an eating disorder.
Emerging trial data suggest GLP-1 medicines effectively reduce binge-eating behaviors, though prolonged appetite suppression requires careful screening to prevent exacerbated restriction.
Over its first fifteen months, the CoRe-ED consortium engaged 960 international registrants across thirty-seven countries to foster cross-disciplinary research and clinical collaboration.
Authors emphasize that routine GLP-1 prescribing must incorporate multidisciplinary care models rather than relying solely on numerical weight-loss metrics to guide treatment decisions.

Summary

This study evaluated the convergence of obesity and eating disorder management prompted by the widespread clinical deployment of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide. Traditional diagnostic frameworks historically segregated obesity and eating disorders into distinct pathological categories. Led by Gemma Sharp at Adelaide University and published in the Journal of Eating Disorders, the research examined how GLP-1 therapies influence binge-eating behavior and appetite suppression, while assessing the operational role of the Consortium for Research in Eating Disorders (CoRe-ED) in facilitating cross-disciplinary care.

Epidemiological evaluations highlight a major therapeutic overlap within the Australian population, where approximately 33.3% of adults live with obesity and 5% (approximately 1.1 million individuals) experience an eating disorder. Over an initial 15-month evaluation period following its launch, CoRe-ED onboarded 960 registrants across 37 countries, encompassing researchers, clinicians, and individuals with lived experience. Additionally, the consortium’s “Next Big Research Idea” initiative mobilized 18 internationally distributed multidisciplinary teams across 20 countries to establish collaborative, co-designed research proposals.

Preliminary clinical findings demonstrate that while GLP-1 receptor agonists reduce binge-eating frequency in select cohorts, unmonitored appetite suppression carries potential risks for vulnerable individuals with eating disorders. The authors conclude that optimal clinical outcomes require moving beyond weight-centric metrics toward multidisciplinary screening and monitoring frameworks. Integrating specialized eating disorder protocols into routine GLP-1 prescribing ensures comprehensive patient safety while addressing shared metabolic and psychological underpinnings.

Link to the article: https://link.springer.com/article/10.1186/s40337-026-01696-6

References

Sharp, G., Hu, H., & Wigley, P. (2026). From establishment to network consolidation: Registrant engagement and collaborative development in the international Consortium for Research in Eating Disorders (Core-ed). Journal of Eating Disorders. https://doi.org/10.1186/s40337-026-01696-6